HC Wainwright Reaffirms “Buy” Rating for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $11.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 48.45% from the company’s previous close. HC Wainwright also issued estimates for Kamada’s Q1 2025 earnings at $0.07 EPS, Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.11 EPS and FY2029 earnings at $0.80 EPS.

Kamada Stock Up 1.2 %

Shares of KMDA opened at $7.41 on Thursday. The business’s 50 day moving average is $7.10 and its two-hundred day moving average is $6.15. Kamada has a 52-week low of $4.74 and a 52-week high of $9.15. The firm has a market cap of $425.93 million, a price-to-earnings ratio of 26.46, a PEG ratio of 0.97 and a beta of 0.99.

Hedge Funds Weigh In On Kamada

A number of institutional investors have recently made changes to their positions in KMDA. Plato Investment Management Ltd acquired a new position in shares of Kamada in the 3rd quarter valued at approximately $117,000. Public Employees Retirement System of Ohio acquired a new position in shares of Kamada in the 3rd quarter valued at approximately $77,000. JPMorgan Chase & Co. acquired a new position in shares of Kamada in the 4th quarter valued at approximately $67,000. NewEdge Advisors LLC raised its position in shares of Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 8,260 shares in the last quarter. Finally, Aristides Capital LLC increased its holdings in shares of Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares during the last quarter. 20.38% of the stock is owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.